<SEC-DOCUMENT>0001299933-15-000318.txt : 20150227
<SEC-HEADER>0001299933-15-000318.hdr.sgml : 20150227
<ACCEPTANCE-DATETIME>20150227164248
ACCESSION NUMBER:		0001299933-15-000318
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20150224
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
FILED AS OF DATE:		20150227
DATE AS OF CHANGE:		20150227

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CHARLES RIVER LABORATORIES INTERNATIONAL INC
		CENTRAL INDEX KEY:			0001100682
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				061397316
		FISCAL YEAR END:			1227

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15943
		FILM NUMBER:		15659892

	BUSINESS ADDRESS:	
		STREET 1:		261 BALLARDVALE STREET
		CITY:			WILMINGTON
		STATE:			MA
		ZIP:			01867
		BUSINESS PHONE:		9786586000

	MAIL ADDRESS:	
		STREET 1:		251 BALLARDVALE ST
		CITY:			WILMINGTON
		STATE:			MA
		ZIP:			01887

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHARLES RIVER LABORATORIES HOLDINGS INC
		DATE OF NAME CHANGE:	19991208
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>htm_51374.htm
<DESCRIPTION>LIVE FILING
<TEXT>
<!-- CoverPageHeader start -->
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<TITLE> Charles River Laboratories International, Inc. (Form: 8-K) </TITLE>
</HEAD>
<BODY TEXT="#000000" BGCOLOR="#FFFFFF" ALINK="#0000FF" HLINK="#FF0000" VLINK="#800080">
<!-- Comment1 -->
<A NAME="DOCUMENT_TOP">&nbsp;</A>
<P>
<!-- CoverPageHeader end --><!-- CoverPageTitle START -->
<A NAME="DOCUMENT_TOP">&nbsp;</A>
<HR NOSHADE>
<P>
<P ALIGN="CENTER">
<FONT SIZE="4">
		UNITED STATES<BR>
	SECURITIES AND EXCHANGE COMMISSION
</FONT>
<BR>
<FONT SIZE="2">
	WASHINGTON, D.C. 20549
</FONT>
<P ALIGN="CENTER">
<FONT SIZE="5">
	FORM 8-K
</FONT>
<FONT SIZE="2">

</FONT>
</P>
<P ALIGN="CENTER">
<FONT SIZE="3">
	CURRENT REPORT
</FONT>
</P>
<P ALIGN="CENTER">
<FONT SIZE="2">
	Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934
</FONT>
</P>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="51%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="44%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Date of Report (Date of Earliest Event Reported):
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	February 24, 2015
</FONT>
</TD>
</TR>
</TABLE>
<BR>
</CENTER>
<!-- CoverPageTitle END --><!-- CoverPageRegistrant START -->
<P ALIGN="CENTER"><!-- -->
<FONT SIZE="6">
	Charles River Laboratories International, Inc.
</FONT>
<FONT SIZE="2">
<BR>__________________________________________<BR>
	(Exact name of registrant as specified in its charter)
</FONT>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="33%">
	&nbsp;
</TD>
<TD WIDTH="34%">
	&nbsp;
</TD>
<TD WIDTH="33%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Delaware
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	001-15943
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	06-1397316
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_____________________<BR>
	(State or other jurisdiction
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_____________<BR>
	(Commission
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
______________<BR>
	(I.R.S. Employer
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	of incorporation)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	File Number)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Identification No.)
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	251 Ballardvale St., Wilmington, Massachusetts
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	01887
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_________________________________<BR>
	(Address of principal executive offices)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
___________<BR>
	(Zip Code)
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">

<TR VALIGN="BOTTOM">
<TD WIDTH="51%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="44%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Registrant&#146;s telephone number, including area code:
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	781-222-6000
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<P ALIGN="CENTER">
<FONT SIZE="2">
	Not Applicable
<BR>______________________________________________<BR>
	Former name or former address, if changed since last report
</FONT>
<P ALIGN="CENTER">
<FONT SIZE="2">
	&nbsp;
</FONT>
<!-- CoverPageRegistrant END --><P><FONT SIZE="2">
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:</FONT>
</P>
<P><FONT SIZE="2">
[&nbsp;&nbsp;]&nbsp;&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<br>
</P></FONT><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><!-- Item START -->
<P ALIGN="LEFT">
<FONT SIZE="2">
<B>
	Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
On February 24, 2015, Charles River Laboratories International, Inc. ("Charles River") announced that Thomas F. Ackerman, Corporate Executive Vice President and Chief Financial Officer, will retire from Charles River Laboratories in February 2016.  Mr. Ackerman joined Charles River in 1988, with over a decade of combined public accounting and international finance experience.  He became Vice President and Chief Financial Officer in 1996 and was elevated to his current position in 2005.  <br><br>David R. Smith, Corporate Senior Vice President, Global Discovery Services, has been named as Mr. Ackerman&#x2019;s successor.  Mr. Smith joined Charles River through the acquisition of Argenta and BioFocus from Galapagos NV, where he was serving as Chief Executive Officer of its Galapagos Services division.  Mr. Smith spent eight years at PricewaterhouseCoopers prior to joining AstraZeneca in 1997, where he spent the next nine years in various finance and business roles of increasingly greater responsibility.  After leaving AstraZeneca, Mr. Smith served as the Chief Financial Officer of Galapagos NV before becoming Chief Financial Officer for Cambridge University Hospitals, where he served in that capacity for six years, from 2007 to 2013.  Mr. Smith will assume Mr. Ackerman&#x2019;s responsibilities over the course of 2015.  <br><br>Charles River has entered into an agreement with Mr. Ackerman effective February 25, 2015 that establishes parameters regarding the gradual and well-planned transition of his responsibilities.  The agreement sets forth that Mr. Ackerman will remain an employee of Charles River until February 29, 2016, after which time he will provide consulting services for another year of at least 125 hours per calendar quarter.  Mr. Ackerman will remain in his current full-time position through August 31, 2015, after which date he and Charles River's Chief Executive Officer will mutually agree on the incremental adjustment of his role and responsibilities through year-end.  Mr. Ackerman&#x2019;s base compensation during the first year of the agreement will be at his current base pay level of $534,465, which will be adjusted to an equivalent hourly rate during the consulting year.   Mr. Ackerman will be eligible to receive his fiscal 2015 cash bonus, but is not eligible for a cash bonus for fiscal 2016.  Mr. Ackerman will receive a grant of long-term equity in 2015 valued at $1 million at the time of grant with a one-year vesting term containing significant performance-based components tied to his satisfactory transition of his current global responsibilities to his successor. Mr. Ackerman will not be eligible to receive any new equity awards in 2016.  The vesting of previously granted equity awards will be unaffected and continue through the conclusion of the consulting period.  In consideration for the benefits provided by the agreement, Mr. Ackerman has waived his rights to other severance benefits to which he otherwise might be entitled.<br><br>
</FONT>
</P>
<!-- Item END -->
<BR><BR><BR><BR><P ALIGN="LEFT" STYLE="FONT-SIZE: 10PT"></P><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><!-- SignatureHeader START -->
<P ALIGN="CENTER">
<FONT SIZE="2">
<B>
	SIGNATURES
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
	Pursuant to the requirements of the Securities Exchange Act of 1934, the
	registrant has duly caused this report to be signed on its behalf by the
	undersigned hereunto duly authorized.
</FONT>
</P>
<!-- SignatureHeader END --><!-- Signature START -->
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="19%">
	&nbsp;
</TD>
<TD WIDTH="34%">
	&nbsp;
</TD>
<TD WIDTH="3%">
	&nbsp;
</TD>
<TD WIDTH="1%">
	&nbsp;
</TD>
<TD WIDTH="43%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" VALIGN="TOP" ALIGN="LEFT">
<FONT SIZE="2">
	Charles River Laboratories International, Inc.
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
<I>
	February 27, 2015
</I>
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	By:
</I>
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Matthew Daniel
</I>
<BR>
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<HR SIZE="1" NOSHADE>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Name: Matthew Daniel
</I>
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Title: Corporate Vice President, Legal Compliance & Deputy General Counsel
</I>
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<!-- Signature END --><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><P ALIGN="CENTER">
<FONT SIZE="2">
	Exhibit&nbsp;Index
</FONT>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="60%">
<TR VALIGN="BOTTOM">
<TD WIDTH="8%">
	&nbsp;
</TD>
<TD WIDTH="15%">
	&nbsp;
</TD>
<TD WIDTH="77%">
	&nbsp;
</TD>
</TR>

<BR>
<TR VALIGN="BOTTOM">
<TD NOWRAP ALIGN="LEFT">
<FONT SIZE="1">
<B>
	Exhibit No.
</B>
</FONT>
</TD>
<TD>
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP ALIGN="LEFT">
<FONT SIZE="1">
<B>
	Description
</B>
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD NOWRAP ALIGN="CENTER">
<HR SIZE="1" NOSHADE>
</TD>
<TD>
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP ALIGN="CENTER">
<HR ALIGN="LEFT" SIZE="1" WIDTH="88%" NOSHADE>
</TD>
</TR>





<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" WIDTH="8%" nowrap>
<FONT SIZE="2">
<DIV ALIGN="LEFT">
	99.1
</DIV>
</FONT>
</TD>
<TD WIDTH="15%">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP" WIDTH="77%">
<FONT SIZE="2">
Agreement between Charles River Laboratories International, Inc. and Thomas F. Ackerman effective February 25, 2015
</FONT>
</TD>
</TR></TABLE></CENTER><!-- HTMLFooter START -->
</BODY>
</HTML>
<!-- HTMLFooter END -->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<TITLE> EX-99.1 </TITLE>
</HEAD>
<BODY TEXT="#000000" BGCOLOR="#FFFFFF" ALINK="#0000FF" HLINK="#FF0000" VLINK="#800080">

<BODY style="font-family: 'Times New Roman',Times,serif">


<P align="center" style="font-size: 10pt"><FONT style="font-size: 12pt"><U><B>AGREEMENT</B></U></FONT>



<P align="left" style="font-size: 12pt; text-indent: 4%">This Agreement (the &#147;Agreement&#148;), with an effective date of February&nbsp;25, 2015, is entered into
by Charles River Laboratories, Inc., with its principal place of business at 251 Ballardvale
Street, Wilmington, Massachusetts 01887 (the &#147;Company&#148;) and Mr.&nbsp;Thomas F. Ackerman, an individual
residing at 11 Atherton Circle, Lynnfield, MA 01940 (the &#147;Employee&#148;).


<P align="left" style="font-size: 12pt; text-indent: 4%">The Employee and the Company recently engaged in discussions regarding the Employee&#146;s future
employment and planned retirement from the Company. The Company desires to afford the Employee the
opportunity to leave in a manner that ensures the smooth transition of his global responsibilities
and allows the Company to benefit from post-employment consulting services to be provided by the
Employee. The Employee desires to provide the Company with the benefit of a smooth and
well-planned transition of the Employee&#146;s responsibilities leading up to the conclusion of his
employment and to provide the Company with post-employment consulting services under mutually
agreeable terms.


<P align="left" style="font-size: 12pt; text-indent: 4%">Consequently, in consideration of the mutual covenants and promises contained herein and other
good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the
parties agree as follows:


<P align="left" style="font-size: 12pt; text-indent: 4%">1.&nbsp;<U>Term of Employment.</U> The Company will continue to employ the Employee until
February&nbsp;29, 2016 (referred to hereafter as the &#147;Final Day of Employment&#148;). The Company agrees to
continue to employ the Employee through the Final Day of Employment, subject to the terms and
conditions specified below and the Employee agrees not to submit his voluntary resignation from
employment with the Company at any time prior to the Final Day of Employment without providing at
least ninety (90)&nbsp;days prior written notice. If the Employee should elect to voluntarily resign by
delivering such notice, he understands and agrees that the first day of the one-year Consulting
Period referenced in Section&nbsp;3 below would be advanced to the first business day following the
effective date of his resignation and would conclude on the one-year anniversary of such date,
which could adversely impact the satisfaction of certain vesting requirements or the lapsing of
certain restrictions under stock awards made to the Employee by the Company, as described in
Section&nbsp;5 of this Agreement.


<P align="left" style="font-size: 12pt; text-indent: 4%">2.&nbsp;<U>Time Commitment.</U> The Company and the Employee have mutually agreed that the amount
of time to be devoted by the Employee to the Employee&#146;s current responsibilities will diminish as
those responsibilities are transitioned to others in anticipation of the Final Day of Employment.
It is currently expected that the Employee will devote the Employee&#146;s full time and attention to
those responsibilities from the date of this Agreement through August&nbsp;31, 2015. During that time,
the Employee and the Chairman, President & CEO of the Company (the &#147;CEO&#148;) will mutually agree on
the incremental adjustment of the Employee&#146;s roles and responsibilities, taking into account the
progressive transitioning of the Employee&#146;s current position responsibilities to his successor.
This adjustment of roles and responsibilities may be modified from time to time by mutual
agreement.


<P align="left" style="font-size: 12pt; text-indent: 4%">3.&nbsp;<U>Consulting Services.</U> The Company desires to benefit from the Employee&#146;s experience
and financial expertise following the Employee&#146;s Final Day of Employment and the Employee is
willing to make his services periodically available to the Company on a consulting basis.
Consequently, the Company and the Employee have agreed that, subject to Section&nbsp;1 above, the
Employee will provide the Company with consulting services (&#147;Consulting Services&#148;) from March&nbsp;1,
2016 through February&nbsp;28, 2017 (the &#147;Consulting Period&#148;). The average number of hours of
Consulting Services to be provided will be established by the CEO, at his sole discretion, but in
no event will the average number of hours of Consulting Services fall below one hundred twenty-five
(125)&nbsp;hours per calendar quarter.


<P align="left" style="font-size: 12pt; text-indent: 4%">4.&nbsp;<U>Salary/Consulting Fees.</U> The Employee will continue to receive his current salary
of $534,465 (the &#147;Base Salary&#148;), paid on a biweekly basis, through the Final Day of Employment.
The Employee understands and agrees that the Employee will receive no base pay adjustment in FY2015
or in FY2016. To the extent that any services will be provided by the Employee working remotely,
either as an employee or as a consultant, the Company will reimburse the Employee for all
reasonable expenses associated with maintaining a home office through the last day of the
Consulting Period. After the Employee converts to consultant status, he will be paid an hourly fee
for Consulting Services equal to his current Base Salary computed at an hourly rate and will be
reimbursed for all reasonable expenses incurred in connection with providing the Consulting
Services.


<P align="left" style="font-size: 12pt; text-indent: 4%">5.&nbsp;<U>Bonus/Stock Awards.</U> The Employee will receive any earned bonus amounts
attributable to: (i)&nbsp;FY2014 performance payable in February, 2015 and (ii)&nbsp;FY2015 performance
payable in February, 2016, consistent with past practices. Similarly, the Employee will retain the
benefit of any stock awards previously made to him by the Company, including continued vesting and
the lapsing of restrictions up to and including the last day of the Consulting Period. The
Employee understands and agrees that he will not participate in the Company&#146;s EICP or any other
bonus programs in FY2016, and that he will not receive any stock award from the Company in FY2016.
The terms and conditions of any stock award agreements underlying any stock awards made to the
Employee by the Company, either prior to or following the execution of this Agreement (collectively
the &#147;Award Agreements&#148;) remain in full force and effect, with the Consulting Period counting toward
the satisfaction of all vesting requirements or the lapsing of any restrictions. All such awards
remain subject to the terms and conditions of the Award Agreements governing the respective awards,
as well as the Company&#146;s 2007 Incentive Plan (the &#147;2007 Plan&#148;). During FY2015, the Employee will
be eligible to receive a stock award from the Company in February, consistent with past practices;
provided, however, that the stock award to be made to the Employee in FY2015 will (i)&nbsp;be valued at
$1&nbsp;million at the time of grant; (ii)&nbsp;be subject to a one-year vesting requirement; and (iii)&nbsp;will
contain a significant performance-based component tied to the Employee&#146;s satisfactory transition of
his current global responsibilities. For purposes of clarity, the provision of Consulting Services
hereunder constitutes a service relationship with the Company, as contemplated by Section&nbsp;4 of the
2007 Plan, which will commence without interruption upon the Employee&#146;s conversion from employee to
consultant status. To the extent that any of the Award Agreements (i)&nbsp;contemplates forfeiture of
an award upon the cessation of employment or other service relationship; or (ii)&nbsp;provides a
specified timeframe for the exercise of vested but unexercised stock option awards following
cessation of such a relationship, the Administrator of the Plan expressly intends that the
provision of Consulting Services under this Agreement constitutes such a service relationship.


<P align="left" style="font-size: 12pt; text-indent: 4%">6.&nbsp;<U>Benefits.</U> The Employee shall be entitled to Company-provided benefits and
coverages including, without limitation, medical/dental coverage, insurance coverage, and
participation in the Company&#146;s 401(k) Plan through the Final Day of Employment. After this date,
the Company will make medical/dental coverage available during the Consulting Period, should the
Employee choose to continue his current coverage. Such coverage will be provided with the Employee
paying the then-current contribution paid by regular full-time employees for his selected coverage.
Following the conclusion of the Consulting Period, the Employee will have the opportunity to
extend his selected coverage under COBRA. The Employee and the Company hereby agree that the
Employee will cease to be eligible for any other Company benefits following the Final Day of
Employment and that no Company contributions will be made to the Company&#146;s Deferred Compensation
Plan on the Employee&#146;s behalf following the Final Day of Employment; provided, however, that any
Company contributions previously made will continue to be maintained and distributed in accordance
with the terms of the Deferred Compensation Plan following the Final Day of Employment.


<P align="left" style="font-size: 12pt; text-indent: 4%">7.&nbsp;<U>Announcement of Retirement/Position Title.</U> The Employee and the CEO will mutually
agree on the date when the Employee&#146;s retirement and pending departure from the Company will be
announced, depending on the pace of the transition. Similarly, if a point is reached where it
helps to better effect the transition, the Employee and the CEO will mutually agree on any title
change that may be necessary in support of the transition. After the Employee converts to
consulting status, his title will be &#147;Senior Financial Advisor&#148;.


<P align="left" style="font-size: 12pt; text-indent: 4%">8.&nbsp;<U>Waiver of Severance.</U> In consideration of the Company&#146;s willingness to enter into
this Agreement, the Employee hereby waives any and all severance benefits the Employee might be
entitled to in connection with the termination of employment and/or the Employee&#146;s resignation as
an employee of the Company, whether contained in a policy, written agreement, or otherwise.
Notwithstanding the foregoing, the Employee specifically retains any benefits made available to
Officers of the Company under the Charles River Corporate Officer Separation Plan (the &#147;Separation
Plan&#148;) in the event the Company elects to involuntarily terminate the Employee&#146;s employment for
reasons other than cause prior to the Final Day of Employment.


<P align="left" style="font-size: 12pt; text-indent: 4%">9.&nbsp;<U>Entire Agreement.</U> This Agreement, together with the Award Agreements, the 2007
Plan, the Separation Plan, and the Amended and Restated Agreement dated February&nbsp;8, 2006 which
affords the Employee certain benefits and protections in the event of a change in control of the
Company while he is employed by the Company, constitute the entire agreement between the parties
and supersede all prior agreements and understandings, whether written or oral, relating to the
subject matter of this Agreement. This Agreement may be amended or modified only by a written
instrument executed by both the Company and the Employee.


<P align="left" style="font-size: 12pt; text-indent: 4%">10.&nbsp;<U>Governing Law</U>. This Agreement shall be construed, interpreted and enforced in
accordance with the laws of the Commonwealth of Massachusetts (regardless of its, or any other
jurisdiction&#146;s choice of law rules).


<P align="left" style="font-size: 12pt; text-indent: 4%">11.&nbsp;<U>Successors and Assigns.</U> The obligations of the Employee hereunder are personal
and shall not be assigned by the Employee. However, the Company may assign its rights and
obligations under this Agreement.


<P align="left" style="font-size: 12pt; text-indent: 4%">12.&nbsp;<U>Miscellaneous.</U> No delay or omission by either party in exercising any right under
this Agreement shall operate as a waiver of that or any other right. A waiver or consent given by
either party on any one occasion shall be effective only if made in writing and only in that
instance, and shall not be construed as a bar or waiver of any right on any other occasion. In the
event that any provision of this Agreement shall be invalid, illegal or otherwise unenforceable,
the validity, legality and enforceability of the remaining provisions shall in no way be affected
or impaired thereby.


<P align="left" style="font-size: 12pt; text-indent: 4%">IN WITNESS WHEREOF, the parties hereto have executed this Agreement effective as of the day
and year set forth above.


<P align="center" style="font-size: 10pt; display: none; text-indent: 4%">1
<!-- PAGEBREAK -->
<DIV align="center">
<TABLE style="font-size: 12pt" cellspacing="0" border="0" cellpadding="0" width="95%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="38%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="57%">&nbsp;</TD>
</TR>
<TR style="font-size: 12pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>CHARLES RIVER LABORATORIES, INC.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>EMPLOYEE</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="font-size: 12pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
</TR>
<TR valign="bottom" style="font-size: 12pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ James C. Foster
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Thomas F. Ackerman</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 12pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">James C. Foster<BR>
Chairman, President &#038; CEO
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Thomas F. Ackerman<BR>
Corporate Executive Vice President &#038; CFO</TD>
</TR>
<TR valign="bottom" style="font-size: 12pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Date:<BR>
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>2/25/15<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>2/17/15<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><BR>
<BR></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt; display: none">2




<!-- v.121908 -->
</BODY>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
